Woodline Partners’s 2seventy bio TSVT Stock Holding History

Woodline Partners’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-958,682	Closed	-$4.09M	–	636
2023 Q4	$4.09M	Buy	+958,682	New	+$2.95M	0.04%	336

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Woodline Partners's TSVT Position: Q1 2024 in Review

Woodline Partners sold out of 2seventy bio (TSVT) in Q1 2024, closing a stake of 958,682 shares — an estimated $4.09M sold.

Woodline Partners first reported a position in TSVT in Q4 2023 and held it in 1 quarter. The position peaked at $4.09M in Q4 2023. 117 funds tracked by Wall St. Rank hold TSVT as of Q1 2024.

Woodline Partners reported no remaining 2seventy bio position as of Q1 2024 after selling out during the quarter.
Woodline Partners sold 958,682 2seventy bio shares in Q1 2024, an estimated $4.09M.
Woodline Partners first reported a position in 2seventy bio in Q4 2023 and held it in 1 quarter.
Woodline Partners's 2seventy bio position peaked at $4.09M in Q4 2023.
117 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.